NEW YORK, Feb 26 (Reuters) - Biotech company Anthera Pharmaceuticals Inc on Friday delayed its initial public offering and set new terms, according to an underwriter.
The company cut its expected price to $7 from an earlier range of $13 to $15 and raised the number of shares it hopes to sell to 6 million from 4.61 million.
The IPO will likely price next week, the underwriter said.
(Reporting by Clare Baldwin) Keywords: ANTHERA/IPO (clare.baldwin@thomsonreuters.com; Reuters Messaging: clare.baldwin.reuters.com@reuters.net; +1 646 223 6189) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The company cut its expected price to $7 from an earlier range of $13 to $15 and raised the number of shares it hopes to sell to 6 million from 4.61 million.
The IPO will likely price next week, the underwriter said.
(Reporting by Clare Baldwin) Keywords: ANTHERA/IPO (clare.baldwin@thomsonreuters.com; Reuters Messaging: clare.baldwin.reuters.com@reuters.net; +1 646 223 6189) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.